This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, D. J. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Cohen, D. J. Articles by Topol, E. J.

Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention

Results from the REPLACE-2 trial

David J. Cohen, MD, MSc^*,,*, A. Michael Lincoff, MD, Tara A. Lavelle, BS, Huei-Ling Chen, PhD, Ameet Bakhai, MD^*,, Ronna H. Berezin, MPH, Daniel Jackman, MD, Ian J. Sarembock, MB, ChB^|| and Eric J. Topol, MD

^* Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Harvard Clinical Research Institute, Brookline, Massachusetts, USA
Mother Frances Hospital, Tyler, Texas, USA
^|| Cardiovascular Division and Cardiovascular Research Center, University of Virginia Health System, Charlottesville, Virginia, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA

View larger version (21K): [in a new window]   Figure 1 Stratified analyses of aggregate 30-day costs by treatment group according to prespecified patient characteristics. The graph indicates the mean difference in costs between the bivalirudin + provisional glycoprotein (GP) IIb/IIIa and heparin + routine GP IIb/IIIa groups (black squares) along with the associated 95% confidence interval (bars). There was no evidence of heterogeneity of treatment effect across any of the subgroups (p value for interaction >0.05).